Kura Oncology
Dr. Leoni joined Kura with more than 10 years of drug development experience, heavily focused within the orphan disease and oncology spaces. During this time, she has held positions of increasing responsibility at pharmaceutical companies both large and small. Most recently, she served as the Executive Director of Medical Science for Kyowa Kirin, serving as the clinical lead for several oncology programs including one that resulted in the successful international registration of a treatment for cutaneous T-cell lymphoma. Dr. Leoni obtained her undergraduate and medical degrees from the University of Pennsylvania, where she also trained extensively in bioethics before entering postgraduate training at Thomas Jefferson University.
This person is not in any offices
Kura Oncology
20 followers
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.